抗肝纤维化中药治疗对肝硬化并发肠系膜上静脉栓塞患者预后的影响

冯颖; 时克; 张晓华; 杨莉; 王宪波

doi:10.3969/j.issn.1001-5256.2022.07.015

抗肝纤维化中药治疗对肝硬化并发肠系膜上静脉栓塞患者预后的影响

DOI: 10.3969/j.issn.1001-5256.2022.07.015

首都医科大学附属北京地坛医院中西医结合中心，北京 100015

基金项目:

国家自然科学基金 (82004153);

北京市科学技术委员会项目 (Z191100006619033)

伦理学声明：本研究方案于2021年3月经由首都医科大学附属北京地坛医院伦理委员会审批，批号：DTZZLX-202103。所纳入患者均签署知情同意书。

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：冯颖负责分析数据、撰写论文；时克负责实施研究并参与修改论文；张晓华、杨莉负责收集病例、患者随访工作、参考文献整理与图表修改；王宪波负责研究设计及审阅、修改论文。

详细信息

通信作者:
王宪波，wangxianbo638@163.com

计量
- 文章访问数: 337
- HTML全文浏览量: 89
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-28
- 录用日期: 2022-05-02
- 出版日期: 2022-07-20

Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

National Natural Science Foundation of China (82004153);

Beijing Science and Technology Project (Z191100006619033)

More Information

Corresponding author: WANG Xianbo, wangxianbo638@163.com (ORCID: 0000-0002-3593-5741)

摘要

摘要: 目的通过抗肝纤维化中药治疗，分析对肝硬化并发肠系膜上静脉栓塞(SMVT)患者生存情况的影响。方法回顾性分析2017年1月—2020年6月在首都医科大学附属北京地坛医院住院治疗的231例肝硬化合并SMVT的患者临床资料，分为中药组(114例)和对照组(117例)。所有患者在针对原发病的常规治疗方案基础上，充分评估抗血栓指征，有必要者均应用标准抗血栓治疗；中药组在此基础上服用抗肝纤维化中药≥6个月。正态分布的计量资料两组间比较采用独立样本t检验；非正态分布的计量资料两组间比较采用Mann-Whitney U检验。计数资料组间比较采用χ²检验。采用Cox回归模型分析影响患者预后的独立性因素；观察患者发生终点事件(死亡)的情况，采用Kaplan-Meier法描绘生存曲线，用log-rank法进行比较检验；根据Child评分分层分析抗肝纤维化中药对不同级别肝功能患者预后的影响，以及不同种类抗肝纤维化中药对患者预后的影响。结果多因素分析显示年龄[风险比(HR)=1.039，95%CI：1.001~1.078，P=0.041]、CRP(HR=1.025，95%CI：1.009~1.041，P=0.003)是患者死亡的独立危险因素，而口服抗肝纤维化中药是保护性因素(HR=0.148，95%CI：0.051~0.429，P=0.001)。生存曲线分析显示中药组生存率高于对照组(95.6% vs 81.2%，χ²=17.032，P＜0.000 1)；进一步分析显示，Child-Pugh A级患者的生存率中药组高于对照组(100% vs 66.7%，χ²=4.003，P=0.045); Child-Pugh B级患者的生存率中药组亦高于对照组(96.7% vs 85.1%，χ²=10.788，P=0.002)。3种抗肝纤维化中药对患者预后影响差异无统计学意义(P＞0.05)。结论年龄、CRP是影响肝硬化并发SMVT患者预后的独立危险因素；抗肝纤维化中药治疗能降低患者的病死率，特别是在Child-Pugh A级及B级患者中疗效更明显。
- 肝硬化 /
- 肠系膜静脉 /
- 静脉血栓栓塞 /
- 中草药
Abstract: Objective To investigate the effect of anti-liver fibrosis traditional Chinese medicine (TCM) therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis (SMVT). Methods A retrospective analysis was performed for the clinical data of 231 patients with liver cirrhosis and SMVT who were hospitalized and treated in Beijing Ditan Hospital, Capital Medical University, from January 2017 to June 2020, and the patients were divided into TCM group with 114 patients and control group with 117 patients. In addition to the conventional treatment regimen for primary diseases, antithrombotic indications were fully evaluated, and standard antithrombotic treatment was applied if necessary; the patients in the TCM group were given anti-liver fibrosis TCM therapy for ≥6 months. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Cox regression model was used to analyze the independent influencing factors for prognosis; outcome events (death) were observed, the Kaplan-Meier method was used to plot survival curves, and the log-rank test was used for comparison; a stratified analysis based on Child score was performed to investigate the effect of anti-liver fibrosis TCM therapy on the prognosis of patients with different liver function grades and the effect of different anti-liver fibrosis TCM drugs on the prognosis of patients. Results The multivariate analysis showed that age (hazard ratio [HR]=1.039, 95% confidence interval [CI]: 1.001-1.078, P=0.041) and C-reactive protein (CRP) (HR=1.025, 95%CI: 1.009-1.041, P=0.003) were independent risk factors for death, while oral administration of anti-liver fibrosis TCM drugs was a protective factor (HR=0.148, 95%CI: 0.051-0.429, P=0.001). The survival curve analysis showed that the TCM group had a significantly higher survival rate than the control group (95.6% vs 81.2%, χ²=17.032, P < 0.0001), and further analysis showed that compared with the control group, the TCM group had significantly higher survival rates of the patients with Child-Pugh grade A/B liver function (Child-Pugh grade A: 100% vs 66.7%, χ²=4.003, P=0.045; Child-Pugh grade B: 96.7% vs 85.1%, χ²=10.788, P=0.002). There was no significant difference in the effect on the prognosis of patients between the three anti-liver fibrosis TCM drugs (P > 0.05). Conclusion Age and CRP are independent influencing factors for the prognosis of patients with liver cirrhosis and SMVT, and anti-liver fibrosis TCM therapy can reduce the mortality rate of patients, especially in the patients with Child-Pugh grade A/B liver function.
- Liver Cirrhosis /
- Mesenteric Veins /
- Venous Thromboembolism /
- Drugs, Chinese Herbal

HTML全文

图 1 中药组和对照组患者的总生存期及根据肝功能分层、中药亚组分析生存情况

注：a，中药组和对照组总生存期情况；b~d，按照肝功分层分析中药组和对照组患者生存情况(b: Child-Pugh A级；c：Child-Pugh B级；d：Child-Pugh C级)；e，按照不同种类中药进行亚组分析患者生存情况。

Figure 1. The overall survival time was analyzed according to liver function or TCM subgroups

下载: 全尺寸图片幻灯片

表 1 231例入组患者的基线情况

Table 1. Baseline characteristics of 231 patients

项目	总体(n=231)	对照组(n=117)	中药组(n=114)	统计值	P值
男/女(例)	173/58	92/25	81/33	χ²=1.76	0.18
年龄(岁)	57.59±11.42	59.10±11.58	56.04±11.08	t=2.05	0.06
酗酒[例(%)]	87(37.66)	45(38.46)	42(36.84)	χ²=0.06	0.80
乙型肝炎[例(%)]	130(56.28)	64(54.70)	66(57.89)	χ²=0.24	0.63
丙型肝炎[例(%)]	21(9.09)	12(10.26)	9(7.89)	χ²=0.39	0.53
酒精性肝病[例(%)]	34(14.72)	20(17.09)	14(12.28)	χ²=1.07	0.30
其他肝病[例(%)]	46(19.91)	21(17.95)	25(21.93)	χ²=0.57	0.45
腹部症状[例(%)]	96(41.56)	52(44.44)	44(38.60)	χ²=0.81	0.37
腹水[例(%)]	185(80.09)	97(82.91)	88(77.19)	χ²=1.18	0.28
消化道出血[例(%)]	104(45.02)	53(45.30)	51(44.74)	χ²=0.01	0.93
肝性脑病[例(%)]	23(9.96)	14(11.97)	9(7.89)	χ²=1.07	0.30
基础疾病[例(%)]	109(47.19)	58(49.57)	51(44.74)	χ²=0.54	0.46
脾切除[例(%)]	55(23.81)	25(21.37)	30(26.32)	χ²=0.78	0.38
门静脉栓塞[例(%)]	177(76.62)	89(76.07)	88(77.19)	χ²=0.04	0.84
WBC(×10⁹/L)	3.65(2.33~5.49)	3.71(2.28~5.30)	3.63(2.35~5.94)	Z=0.21	0.83
Hb(g/L)	89.00(71.20~120.30)	88.00(70.55~122.00)	89.00(72.40~119.63)	Z=0.00	1.00
PLT(×10⁹/L)	83.40(54.00~142.00)	82.40(55.50~141.10)	87.00(52.85~142.30)	Z=0.65	0.52
INR	1.30(1.19~1.43)	1.31(1.19~1.43)	1.30(1.19~1.44)	Z=0.21	0.83
ALT(U/L)	21.60(14.99~35.20)	22.40(14.35~37.90)	21.30(15.83~33.93)	Z=0.03	0.98
AST(U/L)	27.10(18.90~37.50)	26.60(18.25~38.90)	27.25(19.55~35.98)	Z=0.13	0.89
TBil(μmol/L)	17.50(12.80~26.20)	17.80(12.75~27.60)	17.05(12.80~24.70)	Z=1.00	0.32
Alb(g/L)	32.67±5.02	32.12±4.98	33.23±5.01	t=1.68	0.10
BUN(mmol/L)	5.56(4.30~7.55)	5.88(4.34~8.04)	5.15(4.22~7.26)	Z=1.77	0.08
Cr(μmol/L)	66.30(57.75~80.20)	68.65(59.93~81.90)	64.90(53.50~75.60)	Z=2.00	0.06
CRP(mg/L)	3.90(1.20~15.30)	4.90(1.50~20.00)	3.40(1.00~10.89)	Z=1.26	0.21
Child-Pugh分级	7(6~8)	7(6~9)	7(6~8)	Z=1.80	0.07
MELD评分	6.54(3.72~9.35)	7.14(3.93~9.95)	5.92(3.00~8.93)	Z=1.37	0.17
注：BUN, 尿素氮；Cr，血肌酐。

下载: 导出CSV

表 2 影响肝硬化合并SMVT患者预后的单因素及多因素Cox回归分析

Table 2. Univariate and multivariate Cox regression analyses for overall survival of patients with liver cirrhosis complicated with SMVT

变量	单因素分析			多因素分析
变量	β值	HR (95%CI)	P值	β值	HR (95%CI)	P值
性别	-0.180	0.835(0.336~2.075)	0.698
年龄	0.067	1.069(1.034~1.105)	0.001	0.038	1.039(1.001~1.078)	0.041
酗酒	-0.168	0.845(0.38~1.882)	0.680
乙型肝炎	0		0.884
丙型肝炎	0.159	1.172(0.434~3.165)	0.755
酒精性肝病	-0.138	0.871(0.169~4.496)	0.869
其他肝病	-0.384	0.681(0.132~3.518)	0.647
腹水	0.585	1.794(0.617~5.216)	0.283
肝性脑病	0.337	1.401(0.42~4.674)	0.583
腹部症状	0.618	1.856(0.871~3.955)	0.109
消化道出血	-0.079	0.924(0.432~1.975)	0.838
脾切除	0.792	2.207(0.763~6.388)	0.144
基础疾病	0.029	1.029(0.481~2.202)	0.941
门静脉栓塞	0.010	1.010(0.427~2.391)	0.982
中药	-1.802	0.165(0.062~0.437)	0.001	-1.913	0.148(0.051~0.429)	0.001
WBC	0.101	1.106(1.016~1.205)	0.021	0.085	1.089(0.980~1.211)	0.114
Hb	0.002	1.002(0.989~1.015)	0.790
PLT	-0.001	0.999(0.996~1.003)	0.778
INR	1.609	4.997(0.974~25.646)	0.054
ALT	0.005	1.005(0.996~1.014)	0.277
AST	0.009	1.009(1.003~1.015)	0.006	0.001	1.001(0.993~1.008)	0.855
TBil	0.029	1.029(1.011~1.048)	0.001	0.012	1.013(0.983~1.043)	0.407
Alb	-0.030	0.97(0.898~1.049)	0.447
BUN	0.089	1.093(0.989~1.208)	0.083
Cr	0.011	1.011(0.992~1.030)	0.251
CRP	0.032	1.032(1.020~1.044)	0.001	0.025	1.025(1.009~1.041)	0.003
Child-Pugh分级	0.325	1.384(1.101~1.739)	0.005	0.090	1.095(0.820~1.462)	0.540
MELD评分	0.155	1.168(1.051~1.298)	0.004	0.123	1.131(0.988~1.295)	0.075

下载: 导出CSV

参考文献(23)

[1]	JIANG M, LI CL, PAN CQ, et al. Nomogram for predicting transmural bowel infarction in patients with acute superior mesenteric venous thrombosis[J]. World J Gastroenterol, 2020, 26(26): 3800-3813. DOI: 10.3748/wjg.v26.i26.3800.
[2]	CHEN H, XIAO ZX. Diagnosis and treatment strategy of acute mesenteric venous thrombosis[J/CD]. Chin J Vasc Surg(Electronic Version), 2019, 11(1): 7-9. DOI: 10.3969/j.issn.1674-7429.2019.01.003. 陈浩, 肖占祥. 急性肠系膜静脉血栓形成的诊疗策略[J/CD]. 中国血管外科杂志(电子版), 2019, 11(1) : 7-9. DOI: 10.3969/j.issn.1674-7429.2019.01.003.
[3]	ZHANG FX. Modern strategies for the diagnosis and treatment of acute mesenteric ischemic disease[J]. Chin J Pract Surg, 2020, 40(12): 1373-1375. DOI: 10.19538/j.cjps.issn1005-2208.2020.12.08. 张福先. 急性肠系膜缺血性疾病诊治现代策略[J]. 中国实用外科杂志, 2020, 40(12): 1373-1375. DOI: 10.19538/j.cjps.issn1005-2208.2020.12.08.
[4]	DING N, ZHANG XF. Clinical analysis of decompensated liver cirrhosis complicated with acute mesenteric venous thrombosis[J]. J China Presc Drug, 2014, 11: 70-71. DOI: 10.3969/j.issn.1671-945X.2014.11.059. 丁宁, 张学峰. 失代偿期肝硬化合并急性肠系膜静脉血栓的临床分析[J]. 中国处方药, 2014, 11: 70-71. DOI: 10.3969/j.issn.1671-945X.2014.11.059.
[5]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[6]	NIU SS, ZHANG Q, HOU YX, et al. Primary preventive effect of anti-fibrosis treatment on esophageal and gastric varices bleeding in patients with cirrhosis: a real-world study[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006. 牛帅帅, 张群, 侯艺鑫, 等. 抗肝纤维化治疗对肝硬化食管胃静脉曲张出血的一级预防作用[J]. 中西医结合肝病杂志, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006.
[7]	LIU Q, XU X, WANG ZG. Effect of calycosin on intestinal mucosal barrier function in cirrhosis rats and its mechanism[J]. J Jilin Univ(Med Edit), 2022, 294(2): 391-398. DOI: 10.13481/j.1671-587X.20220216. 刘琦, 徐新, 王正根. 毛蕊异黄酮对肝硬化大鼠肠黏膜屏障功能的影响及其机制[J]. 吉林大学学报(医学版), 2022, 294(2): 391-398. DOI: 10.13481/j.1671-587X.20220216.
[8]	HOU YX, YANG ZY, YANG YY, et al. Clinical effect of Liqi Jianpi prescription in preventing hemorrhage within one year in patients with hepatitis B cirrho-sis and severe esophageal and gastric varices[J]. J Clin Hepatol, 2019, 35(4): 780-784. DOI: 10.3969/j.issn.1001-5256.2019.04.015. 侯艺鑫, 杨志云, 杨玉英, 等. 理气健脾方预防乙型肝炎肝硬化合并重度食管胃底静脉曲张患者1年内出血的疗效评价[J]. 临床肝胆病杂志, 2019, 35(4): 780-784. DOI: 10.3969/j.issn.1001-5256.2019.04.015.
[9]	WANG XB, LIU P, TANG ZP, et al. Cordyceps mycelia extract decreases portal hypertension in rats with dimethylnitrosamine-induced liver cirrhosis: a study on its histological basis[J]. J Chin Integr Med, 2008, 6(11): 1136-1144. DOI: 10.3736/jcim20081107. 王宪波, 刘平, 唐志鹏, 等. 冬虫夏草菌丝提取物降低二甲基亚硝胺大鼠肝硬化门静脉高压效应的组织学基础[J]. 中西医结合学报, 2008, 6(11): 1136-1144. DOI: 10.3736/jcim20081107.
[10]	LIU XN. Efficacy and safety analysis of acupuncture combined with traditional Chinese medicine in the treatment of sequelae of cerebral thrombosis[J]. Chin J Mod Drug Appl, 2021, 15(8): 197-199. DOI: 10.14164/j.cnki.cn11-5581/r.2021.08.078. 刘晓宁. 针灸联合中药治疗脑血栓后遗症的疗效及安全性分析[J]. 中国现代药物应用, 2021, 15(8): 197-199. DOI: 10.14164/j.cnki.cn11-5581/r.2021.08.078.
[11]	WANG ZC, GU EL, WANG SP, et al. Effect of alprostadil combined with traditional Chinese medicine Buyang Huanwu decoction in the treatment on liver cirrhosis with portal vein thrombosis[J]. J Emerg Tradit Chin Med, 2017, 26(2): 311-314. DOI: 10.3969/j.issn.1004-745X.2017.02.041. 王忠成, 顾尔莉, 王世蓬, 等. 前列地尔联合补阳还五汤治疗门静脉血栓症的疗效观察[J]. 中国中医急症, 2017, 26(2): 311-314. DOI: 10.3969/j.issn.1004-745X.2017.02.041.
[12]	WANG HX, HAN SN. Research progress of traditional Chinese medicine injection for blood-activating and stasis-resolving in the prevention and treatment of deep venous thrombosis[J]. China Modern Med, 2016, 23(6): 22-24. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201606009.htm 王惠霞, 韩世妮. 活血化瘀中药注射剂防治深静脉血栓形成的研究进展[J]. 中国当代医药, 2016, 23(6): 22-24. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201606009.htm
[13]	FAN WJ, HU XM, HUANG RY, et al. Chinese medicine injection for promoting blood circulation and removing blood stasis combined with low molecular heparin on postoperative DVT: an overview of systematic reviews[J]. J Emerg Tradit Chin Med, 2020, 29(8): 1356-1360. DOI: 10.3969/j.issn.1004-745X.2020.08.012. 樊炜静, 胡啸明, 黄仁燕, 等. 活血化瘀类中药注射剂联合低分子肝素防治术后深静脉血栓形成疗效和安全性的系统评价再评价[J]. 中国中医急症, 2020, 29(8): 1356-1360. DOI: 10.3969/j.issn.1004-745X.2020.08.012.
[14]	CHEN R, CHEN PP, LIN CC, et al. Comparison of mesenteric vascular ultrasound and CTA in the diagnosis of emergency acute mesenteric vascular embolism[J]. China Med Herald, 2021, 18(17): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202117029.htm 程瑞, 陈佩佩, 林姹姹, 等. 肠系膜血管超声与CTA对急诊急性肠系膜血管栓塞的诊断对比[J]. 中国医药导报, 2021, 18(17): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202117029.htm
[15]	WANG QY, WU MF, LIU X, et al. Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021[J]. Chin J Clin Pharmacol, 2021, 37(21): 2999-3016. DOI: 10.13699/j.cnki.1001-6821.2021.21.032. 王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. DOI: 10.13699/j.cnki.1001-6821.2021.21.032.
[16]	YANG L, FENG Y, ZHOU GQ, et al. Clinical characteristics of 254 patients with chronic liver disease complicated with superior mesenteric vein embolism[J]. Mod Digest Interv, 2021, S1(26): 137-139. 杨莉, 冯颖, 周桂琴, 等. 254例慢性肝病并发肠系膜上静脉栓塞患者的临床特征分析[J]. 现代消化及介入诊疗, 2021, S1(26): 137-139.
[17]	LI X. Clinical thinking of Wang Xianbo in the treatment of hepatitis B cirrhosis[J]. Beijing J Tradit Chin Med, 2015, 34(9): 713-716. DOI: 10.16025/j.1674-1307.2015.09.011. 李向. 王宪波治疗乙型肝炎肝硬化的临证思路[J]. 北京中医药, 2015, 34(9): 713-716. DOI: 10.16025/j.1674-1307.2015.09.011.
[18]	JIANG Y. Preliminary discussion on blood stasis syndrome in Yilin Gaicuo[J]. J Beijing Univ Chin Med, 2014, 37(3): 152-155, 164. DOI: 10.3969/j.issn.1006-2157.2014.03.002. 蒋燕. 《医林改错》瘀血病证的初步探讨[J]. 北京中医药大学学报, 2014, 37(3): 152-155, 164. DOI: 10.3969/j.issn.1006-2157.2014.03.002.
[19]	GU SN, JIANG TW. Clinical application and experimental research progress of activating blood and removing stasis drugs for treating thrombotic diseases[J]. J Changchun Univ Chin Med, 2019, 35(2): 382-384, 388. DOI: 10.13463/j.cnki.cczyy.2019.02.053. 谷胜男, 姜彤伟. 活血化瘀药治疗血栓性疾病的临床应用及实验研究进展[J]. 长春中医药大学学报, 2019, 35(2): 382-384, 388. DOI: 10.13463/j.cnki.cczyy.2019.02.053.
[20]	LIU JL. Study on the antithrombotic effect of huoxue huayu drugs[J]. China Modern Med, 2013, 20(35): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201335007.htm 柳吉玲. 活血化瘀药抗血栓作用的研究进展[J]. 中国当代医药, 2013, 20(35): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201335007.htm
[21]	CHEN J, DENG J, ZHOU J, et al. Metabonomic study of traditi. onal Chinese herb pair, Qinghao-Biejia in treating systemic lupus erythematosus mice[J]. Chin Pharmacol Bull, 2016, 32(5): 727-731, 732. DOI: 10.3969/j.issn.1001-1978.2016.05.026. 陈娟, 邓军, 周佳, 等. 青蒿-鳖甲药对配伍治疗系统性红斑狼疮小鼠的代谢组学研究[J]. 中国药理学通报, 2016, 32(5): 727-731, 732. DOI: 10.3969/j.issn.1001-1978.2016.05.026.
[22]	LI YS, LI S. Research progress and review on the mechanism of promoting blood circulation and removing blood stasis drugs in the prevention and treatment of thrombosis[C]// Proceedings of the Fifth National Academic Exchange Conference on the prevention and treatment of thrombosis by traditional Chinese medicine and the new election meeting of thrombosis branch of Chinese society of traditional Chinese medicine, 2011: 198-205. 李佑生, 黎帅. 活血化瘀药防治血栓病机制研究进展及述评[C]//第五次全国中医药防治血栓病学术交流会暨中华中医药学会血栓病分会换届改选工作会议论文集, 2011: 198-205.
[23]	ZHANG Y, HOU GM, LIU XM, et al. Study on the medication rule of containing insect drugs in the treatment of deep venous thrombosis based on data mining[J]. J Liaoning Univ Tradit Chin Med, 2021, 23(3): 1518. DOI: 10.13194/j.issn.1673-842x.2021.03.004. 张玥, 侯光敏, 刘效敏, 等. 基于数据挖掘含虫类药物组方治疗深静脉血栓形成的用药规律研究[J]. 辽宁中医药大学学报, 2021, 23(3): 1518. DOI: 10.13194/j.issn.1673-842x.2021.03.004.